Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

1. Banerjee, S.
2. Moore, K.N.
3. Colombo, N.
4. Scambia, G.
5. Kim, B.-G.
6. Oaknin, A.
7. Friedlander, M.
8. Lisyanskaya, A.
9. Floquet, A.
10. Leary, A.
11. Sonke, G.S.
12. Gourley, C.
13. Oza, A.
14. González-Martín, A.
15. Aghajanian, C.
16. Bradley, W.H.
17. Holmes, E.
18. Lowe, E.S.
19. DiSilvestro, P.